Corcept Therapeutics And 2 Other Growth Stocks With Significant Insider Ownership

Over the last 7 days, the United States market has experienced a 1.4% drop, yet it remains up by 16% over the past year with earnings projected to grow by 18% annually. In this context, growth companies with significant insider ownership can be particularly appealing as they often signal strong internal confidence and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
XCHG (XCH)	39.7%	102.2%
Uxin (UXIN)	34.3%	69.4%
Upstart Holdings (UPST)	14.1%	59.9%
Super Micro Computer (SMCI)	12.8%	25.4%
Karman Holdings (KRMN)	15.6%	52.6%
IREN (IREN)	13.6%	41.2%
ERock (EROC)	20.1%	56.3%
Corcept Therapeutics (CORT)	10.8%	47.8%
Cerebras Systems (CBRS)	11%	73.7%
AppLovin (APP)	23.2%	21.7%

Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Corcept Therapeutics (CORT)

Simply Wall St Growth Rating: ★★★★★★

Overview: Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of approximately $10.27 billion.

Operations: The company's revenue is primarily derived from the discovery, development, and commercialization of pharmaceutical products, amounting to $769.10 million.

Insider Ownership: 10.8%

Corcept Therapeutics is poised for substantial growth, with its revenue expected to outpace the US market significantly. Despite a decline in profit margins from the previous year, earnings are projected to grow robustly. Insider activity shows more buying than selling recently, though not in large volumes. Recent developments include resubmitting an NDA for relacorilant and FDA approval of Lifyorli, enhancing its product pipeline despite being dropped from key indices recently.

• Navigate through the intricacies of Corcept Therapeutics with our comprehensive analyst estimates report here.
• Insights from our recent valuation report point to the potential overvaluation of Corcept Therapeutics shares in the market.

Strive (ASST)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Strive, Inc. is a privately owned investment manager with a market cap of approximately $1.09 billion.

Operations: Revenue segments for Strive, Inc. include various investment management services totaling $1.09 billion.

Insider Ownership: 12.2%

Strive, Inc. is on a growth trajectory with revenue increasing by 66.1% over the past year and earnings forecasted to grow significantly at 162.6% annually. However, it faces challenges with high volatility in its share price and recent exclusion from several Russell indices, which may impact investor sentiment. Despite these hurdles, Strive's projected profitability within three years suggests potential for above-average market growth, although insider trading activity remains unclear recently.

• Unlock comprehensive insights into our analysis of Strive stock in this growth report.
• Our comprehensive valuation report raises the possibility that Strive is priced higher than what may be justified by its financials.

Precigen (PGEN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies targeting diseases in immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of approximately $1.96 billion.

Operations: Revenue for Precigen primarily comes from its biotechnology startups segment, totaling $31.60 million.

Insider Ownership: 11.8%

Precigen is poised for significant growth, with revenue expected to increase by 42.4% annually, surpassing the US market average. The company recently achieved FDA approval and seven-year exclusivity for PAPZIMEOS, a pioneering therapy for recurrent respiratory papillomatosis. Despite these advancements, Precigen faces challenges including substantial insider selling and dilution over the past year, alongside being dropped from multiple Russell indices which could affect investor perception. However, it trades significantly below its estimated fair value.

• Get an in-depth perspective on Precigen's performance by reading our analyst estimates report here.
• According our valuation report, there's an indication that Precigen's share price might be on the expensive side.

Key Takeaways

• Delve into our full catalog of 176 Fast Growing US Companies With High Insider Ownership here.
• Seeking Other Investments? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com